RT @doctorRBC: Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2âï¸sustained DAPSA LDA/re
Tweet Content
Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
On